TLDR Cantor Fitzgerald upgraded Alphabet to Overweight, raising price target to $370 from $310 Gemini’s market share jumped to over 20% from under 6% in 12 monthsTLDR Cantor Fitzgerald upgraded Alphabet to Overweight, raising price target to $370 from $310 Gemini’s market share jumped to over 20% from under 6% in 12 months

Alphabet (GOOGL) Stock: Google’s Gemini AI Gains Ground as Market Cap Tops Apple

TLDR

  • Cantor Fitzgerald upgraded Alphabet to Overweight, raising price target to $370 from $310
  • Gemini’s market share jumped to over 20% from under 6% in 12 months, while ChatGPT fell to under 65% from 85%
  • Alphabet briefly surpassed Apple in market cap this week, reaching $3.89 trillion for the first time since 2019
  • Analysts believe Google’s integration of search, maps, and payment data gives Gemini a competitive edge
  • Alphabet stock has climbed 66% over the past 12 months, now trading at 28.6 times forward earnings

Alphabet shares rose over 2% Wednesday as Wall Street analysts turned more bullish on Google’s position in the AI race. The company briefly overtook Apple in market value for the first time since 2019.


GOOGL Stock Card
Alphabet Inc., GOOGL

Cantor Fitzgerald analyst Deepak Mathivanan upgraded Alphabet to Overweight from Neutral Wednesday. The firm raised its price target to $370 from $310.

Shares traded at $324.51 in premarket hours Thursday, up 0.8%. The stock has gained 66% over the past year.

The upgrade comes as Google’s Gemini AI gains traction against OpenAI’s ChatGPT. Website traffic data from Similarweb shows Gemini now holds over 20% market share, up from less than 6% just one year ago.

ChatGPT’s share fell to under 65% from roughly 85% in the same period. OpenAI still leads with around 900 million weekly active users versus Gemini’s 650 million monthly active users.

But momentum appears to be shifting. Google launched its Nano Banana image tool in August and Gemini 3 model in November. Both releases attracted users away from competitors.

Google’s Data Advantage

Cantor analysts see Google pulling ahead as AI moves toward “practical usefulness” rather than just raw model intelligence. The company’s decade of search technology development gives it an edge.

Google can feed Gemini data from search, maps, and payment systems. This integration will matter more as AI agents become mainstream.

AI agents handle multistep tasks based on simple instructions. Users will likely stick with one assistant for these functions. Google’s data ecosystem positions Gemini as the more useful choice.

Market Cap Battle

Alphabet’s market cap hit $3.89 trillion Wednesday while Apple dropped to $3.86 trillion. The shift reflects investor confidence in Google’s AI strategy.

Jefferies analysts noted stronger engagement and rising downloads from AI features across Google’s consumer apps. They expect this momentum to drive long-term revenue growth.

Apple hasn’t launched a major AI platform since Apple Intelligence in 2024. The company appears to be falling behind in the AI race.

Alphabet has multiple revenue drivers working in its favor. Ad sales remain steady while cloud performance expands. AI product rollouts continue at a rapid pace.

The company is developing custom tensor processing units for AI computing. These chips target Nvidia’s dominance in the sector.

Alphabet now trades at 28.6 times forward earnings, up from its five-year average of 21.7 times. Cantor’s $370 price target assumes a 30 times price-to-earnings ratio based on blended fiscal 2026 and 2027 earnings estimates.

Alphabet shares climbed more than 2% Wednesday, pushing the company past Apple in total market value for the first time in seven years.

The post Alphabet (GOOGL) Stock: Google’s Gemini AI Gains Ground as Market Cap Tops Apple appeared first on Blockonomi.

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26